UNSPSC 51391734: Phenylephrine

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1WS297W6MV, chemically known as tannins, compds. with (r)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol but generally known as phenylephrine, which bears US NIH Compound Identifier 6041. European Medicines Agency schedules Phenylephrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09788MIG.

UNSPSC 51391734 Phenylephrine is a Commodity code for pharmaceutical products, but the recent state and local activity tagging this code shows little direct relevance to phenylephrine itself. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to support community health initiatives and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting models between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. Neither solicitation targets phenylephrine procurement specifically, and the code appears to be misapplied to these broader pharmaceutical-distribution and pharmacy-benefit-management activities.

The issuing bodies include a county health department and a state health and human services commission, indicating that pharmaceutical and prescription-management solicitations span local public-health entities and state-level health agencies. Geographic activity appears concentrated in Florida and Texas based on recent postings. The mismatch between the code's nominal scope (phenylephrine, an active pharmaceutical ingredient) and the actual work being procured (naloxone products and direct-to-manufacturer prescription program infrastructure) suggests this Commodity code does not reliably capture current state and local phenylephrine demand or related pharmaceutical acquisitions. Firms evaluating activity under this code should verify code assignments in actual RFPs and RFQs rather than relying on the UNSPSC classification alone.